Global Anti-Nerve growth factor market 2027: Top Key Players Eli Lilly & Company, Pfizer, Regeneron Pharmaceuticals; Sanofi-aventis, Mitsubishi Tanabe Pharma Corporation, Teva Pharmaceutical Industries, Astellas Pharma, etc

Nerve growth factor is a tumor tissue produced growth factor that promotes the growth and differentiation of sympathetic and sensory ganglia. It is first growth factor to be identified. Elevated level of nerve growth factor leads to inflammation and peripheral nerve injury. The nerve growth factor is secreted in the body following stimulus (eg, chemical, thermal, or mechanical). Clinically, elevated level of nerve growth factor in the body leads to chronic pain conditions like chronic headaches, diabetic neuropathy, interstitial cystitis, arthritis, pancreatitis, prostatitis, cancer pain, and noncancerous pain. Current pain management therapy has certain limitation and fails to meet current clinical needs. The discovery of nerve growth factor has been well characterized as important mediators of pain management. Pharmacotherapies targeting this nerve growth factor are considered to have the potential in the treatment of a variety of nociceptive and neuropathic pain conditions.

Request For Sample @ https://bit.ly/2VM0viy

Currently, molecules targeting nerve growth factor are in pipeline and are expected to come into the market in forecast period. Tanezumab is most attractive and-NGF antibody which is currently in phase 3 of clinical stage development for various different indications which includes back pain, cancer pain, musculoskeletal pain, and other pain. It is developed by Pfizer in collaboration with Eli Lilly & Company. In 2017, FDA granted fast track designation for tanezumab for the treatment of osteoarthritis and for chronic low back pain. Other anti-NGF antibody currently in pipeline includes fulranumab, ASP6294, Fasinumab, and others. Entry of anti-NGF antibody into the market will fulfill the current unmet need of pain management therapeutics. The treatment algorithm for pain management will change significantly during forecast period with the fasinumab and tanezumab holding significant share of the market over the next decade. Increase in incidence and prevalence of inflammatory disease like osteoarthritis, etc and related disorders, growing demand for novel therapies and current unmet need from commercially available option drives the growth of anti-nerve growth factor antibody market during forecast period. However, disappointing results of promising pipeline molecules hampers the growth of the market during forecast period.

At regional level, the global anti-nerve growth factor antibody has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. In terms of revenue, North America followed by Europe is major contributor for the global anti-nerve growth factor antibody market. This is because strong clinical pipeline, increasing research and drug development activities, presence of major players, and presence of developed healthcare infrastructure propels the growth of the market in the region. Asia Pacific is third promising revenue contributor which is expected to grow at rapid pace in upcoming year. Countries such as Japan, India and China are major contributors for this market. Rising demands for novel therapies and emerging and huge population base countries such as China and India offers tremendous market opportunities for the anti-nerve growth factor antibody.

Request For Table Of Content (TOC) @ https://bit.ly/2VM0viy

Some of the market players leading the global anti-nerve growth factor antibody market include Eli Lilly & Company, Pfizer, Regeneron Pharmaceuticals; Sanofi-aventis, Mitsubishi Tanabe Pharma Corporation, Teva Pharmaceutical Industries, Astellas Pharma, etc

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products.

Contact Us:
Mr. John Smith
InsightAce Analytic Pvt. Ltd.
Pune, Maharashtra, India
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: https://www.insightaceanalytic.com
Follow Us on LinkedIn @ https://bit.ly/2tBXsgS
Follow Us On Facebook @ https://bit.ly/2H9jnDZ

This release was published on openPR.